Work

Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.2624

Authors: Michael L. Maitland, Sai-Hong Ignatius Ou, Anthony W. Tolcher, Patricia LoRusso, Erkut Bahceci, Howard A Ball, Jung Wook Park, Geoff Yuen, Luana Pesco Koplowitz, Tianhong Li

Institutions: University of Chicago, UC Irvine Chao Family Comprehensive Cancer Center, South Texas Accelerated Research Therapeutics, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Astellas Pharma (United States), University of California Davis Medical Center, UC Davis Comprehensive Cancer Center, University of California, Davis

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2592630381

Cites:

Cited by: 21

Related to: 10